A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model

Masato Saito, Kana Kunieda, Toshihiko Ishii, Shoko Koshiba, Rui Ohashi, Yutaka Kanda, Takuji Yamada · 2025

Read A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model by Masato Saito, Kana Kunieda, Toshihiko Ishii, Shoko Koshiba, Rui Ohashi, Yutaka Kanda, Takuji Yamada (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717313.txt.

Description

Masato Saito and six co-authors report a lab study, published in twenty twenty-five, on a drug called KHK2455 in mice with skin tumors. The drug blocks an enzyme that helps tumors grow by breaking down a key amino acid. Alone, the drug lowered the waste product of that process but did not shrink the tumors.

Paired with a second treatment that blocks a brake on immune cells, the drug worked much better than that treatment alone. The two treatments acted on different arms of the immune system. One woke up helper T cells, while the other raised the number of killer cells and other first-line defenders. Together they turned on both arms at once, a result that may guide future paired treatment plans.

Catalog record

CREATORMasato Saito, Kana Kunieda, Toshihiko Ishii, Shoko Koshiba, Rui Ohashi, Yutaka Kanda, Takuji Yamada
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12717313

Browse the full library · About the Tower of Babel